Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention

Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00164008

Enrollment

Registered

2005-09-14

Start date

2002-10-31

Completion date

2005-12-31

Last updated

2013-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications of Heart-lung Transplant, Osteopenia, Other Complications of Lung Transplant

Brief summary

The purpose of this trial is to see whether zoledronic acid is better than pamidronate to treat low bone density in heart and lung transplant patients.

Interventions

DRUGzoledronic acid vs pamidronate

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* reduced bone density as indicated by a bone density T score \<-1.in either the lumbar spine or femoral neck * have undergone or are on the waiting list for heart or lung transplantation * are receiving adequate calcium and vitamin D therapy * have provided written informed consent prior to participation in the trial

Exclusion criteria

* untreated hypogonadism, hypothyroidism or hyperthyroidism * acute or major organ rejection or intercurrent illness * pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Bone mineral density of lumbar spine at 12 months as measured by DEXA.	—

Secondary

Measure	Time frame
Bone mineral density of femoral neck at 12 months as measured by DEXA.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026